Clinical Trial Update: Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, and antiviral activity of selgantolimod in virally-suppressed adults with chronic hepatitis B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Selgantolimod (Selgantolimod)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis B | Phase 2 | Status: COMPLETED | Results posted: 2020-04-01